Meta-analyses by Agache et al. [51, 52, 53] have shown a slightly increased rate (low to medium risk of association) of adverse events when anti-IL-5/5R, anti-IL-4/13R, and anti-IgE are used in severe asthma, independently of COVID-19. The gene discussed is IGHE; the disease is COVID-19.